Robert Huizinga
Tracked across 4 events · 26 articles · First seen May 29, 2026 · Last active Sep 09, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Kane Biotech Inc., a biotechnology company focused on microbial biofilms and wound care, announced on September 9, 2026, that it will host a virtual Commercial Update webcast on September 16, 2026. The webcast will feature…
Impact: Dr. Robert Huizinga, Interim CEO, will present operational and commercial updates, outlining the company's execution priorities.
Sep 09, 2026 · 6 articles
Business
Impact: Robert Huizinga is the Interim CEO of Kane Biotech and is among the recipients of the stock options.
May 29, 2026 · 6 articles
Business
Impact: As Interim CEO, Robert Huizinga is focused on executing commercial objectives while evaluating strategic initiatives, playing a key role in the review process.
Aug 05, 2026 · 7 articles
Tech
Impact: Dr. Robert Huizinga, Interim CEO, commented on the interest generated, representing the company's leadership in this development.
Aug 25, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Robert Huizinga live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard